

Exhibit 195

Executive Summary

for Litigation of PLANDEMIC Crimes | Dr. David E. Martin

EXECUTIVE SUMMARY

for Litigation of PLANDEMIC Crimes | Dr. David E. Martin

OUR PURPOSE

This Executive Summary provides a brief review of the felonious actions of a criminal organization and its flagrant attempt to extort and obtain control over the global population. It has sought to do so by creating patented bioweapons marketed as novel viruses and immunizations ... immunizations hailed as health security for the world in the 21st century – titled by them as “The Century of the Vaccine.” The facts detailed in this Executive Summary are part of the public record and are identified herein as primary source material.

The purpose of providing the chronological timeline of events, supporting documents, and individual and corporate participants involved in this criminal syndicate is to dissolve the protective anonymity of the parties involved, expose who they are, and detail the specific crimes they have committed for commercial gain and political power.

Why? We intend to prosecute them for those crimes, to obtain justice, and to achieve monetary relief for the millions who have been injured and who have died at their hands. This incalculable injustice is the result of the criminal malfeasance of the individuals and organizations who forced the implementation of their experiment-in-a-syringe upon the world. We stand for, protect, and defend humanity ... you our brothers and sisters, fellow citizens of this earth.

All monies obtained pursuant to such prosecutions will be distributed to those who have suffered any injury from the commission of these crimes.

Any monies contributed to support these efforts are used exclusively for the purpose of pursuing the investigations and prosecutions of the perpetrators and providing justice and relief to the injured.

THE OBJECTIVE

Our immediate objective is to organize and amplify your individual voice and the collective citizen voices in the ears of our elected state officials for the singular purpose of demanding and obtaining the appointment of special prosecutors to initiate and pursue criminal proceedings against the perpetrators.

ACT I, SCENE I

- Time and place: Spring 2005, United Nations (UN) (World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Geneva, Switzerland
- Event: Global Immunization Vision and Strategy 2006-2015 (GIVS) Meeting
- Purpose: Launch GIVS 2006-2015.¹
- Actors: Lee-Jong Wook, Director-General WHO (representing member states of WHO and World Health Assembly (WHA)); Ann N. Veneman, Executive Director, UNICEF (representing its Executive Board);² WHO and UNICEF, who jointly drafted a global immunization vision and strategy for the years 2006–2015;³ Global Alliance for Vaccines and Immunization (GAVI)⁴ and its financing arm, The Vaccine Fund
- Statements: “[We, the WHO]/UNICEF] launch the first 10-year strategic framework to realize the potential of immunization....⁵

¹ Global Immunization Vision and Strategy 2006-2015, published, printed October 2005, https://apps.who.int/iris/bitstream/handle/10665/69146/WHO_IVB_05.05.pdf;sequence=1.

² Id. p.3. For membership of the UNICEF Executive Board from 1946 -2021, see www.unicef.org/executiveboard/media/6626/file/2021-EB_Composition-EN-2021.07.29.pdf.

³ Id. Executive Summary, p. 6.

⁴ GAVI headquarters are located in Washington DC, USA; Geneva, Switzerland. “GAVI was launched in 2000 to fund the procurement and delivery of vaccines for the world’s poorest countries. GAVI was established by a Meeting of the Proto-Board in Seattle on 12 July 1999 (See Decision GAVI/99.01) as an alliance of public and private sector organizations, institutions and governments, including the Bill & Melinda Gates Foundation, UNICEF, the World Bank, WHO, vaccine manufacturers, NGOs and research and technical health institutes. In 2008, the GAVI Alliance, the GAVI Fund (a non-profit organization based in the United States) and the GAVI Foundation were reorganized under the GAVI Alliance brand, using the GAVI Foundation’s legal platform. The legal entity, The GAVI Alliance, is a Foundation under Swiss law with international institution status and has Public Charity status in the United States.” https://www.who.int/phi/documents/gavi_alliance.pdf?ua=1. “The GAVI Alliance Board is the supreme governing body. It comprises: four permanent members, WHO, UNICEF, the World Bank and the Bill and Melinda Gates Foundation; GAVI Alliance CEO (non-voting); nine independent individuals; and representative seats from developing (5) and industrialized (5) governments; vaccine industries in developing (1) and industrialized (1) countries; research and technical institutes (1); and civil society organizations (1).” Id.

⁵ *Draft Global Vaccine Action Plan*, p.1 para. 2, [Microsoft Word - A65_22-en.docx \(who.int\)](#); see also 2; World Health Organization. Draft global immunization strategy [WHA 58.15, agenda item 13.8]. Geneva, Switzerland: World Health Organization; 2005. See United Nations Children's Fund. UNICEF Executive Board Decision 2005/7. UNICEF/WHO Global immunization vision and strategy. New York, NY: United Nations Children's Fund; 2005. Available at http://www.unicef.org/about/execboard/files/2005-7_UNICEF_WHO.pdf

“The realization of this vision *of immunization will need strengthened surveillance*, monitoring and evaluation, and the application of solid data for programme management.... Immunization remains an unfinished agenda....⁶

“In today’s increasingly interdependent world, acting together against vaccine-preventable diseases of public health importance and *preparing for the possible emergence of diseases with pandemic potential* will contribute significantly to improving global health and security.⁷

“Governments, WHO, UNICEF, vaccine manufacturers and research institutes are currently involved in efforts to support the development of national preparedness plans and to expand capacity for production of influenza vaccine worldwide, including work on *the development of a new vaccine against virus strains with pandemic potential*.”⁸ (Emphasis added.)

⁶ Global Immunization Vision and Strategy 2006-2015, Executive Summary, p. 6, https://apps.who.int/iris/bitstream/handle/10665/69146/WHO_IVB_05.05.pdf;sequence=1. GIVS 2006-2015 uses the term “surveillance” 84 times in its program document. Policies and strategies regarding all immunization matters become the province of the WHO: “The choice of policies, strategies and practice is informed by data from operational research, surveillance, monitoring and evaluation, disease burden and impact assessments, and economic analyses, and by the sharing of lessons and experiences from countries in similar circumstances. Id. at 16.

⁷ Id. at 17.

⁸ Id at 24.

ACT I, SCENE II

Time and Place: 2006, Massachusetts Institute of Technology, Cambridge, MA

Event: MIT Library, Compilation of Technical Reports in Support of Sloan Foundation Study on DNA synthesis and governance options.⁹

Purpose: Working Papers for Synthetic Genomics: Risks and Benefits for Science and Society.¹⁰ Dr. Ralph Baric presented the malleability of coronavirus as a biological warfare agent and inducing the non-competitive market allocation for years to follow,¹¹ violating 18 USC § 175 (regarding prohibitions of biological weapons)¹² and 15 USC § 8 (regarding illegal Trusts in restraint of import trade).¹³

Actors: Ralph Baric, MIT, Sloan Foundation

Statements: “[V]iruses of humans, animals and plants . . . are ...potential weapons of mass disruption to human populations, critical plant and animal food sources, and national economies.... *Biological warfare (BW) agents are microorganisms or toxins that are intended to kill, injure or incapacitate the enemy, elicit fear and devastate national economies....* This report discusses the potential use of recombinant and synthetic¹⁴ DNAs to resurrect recombinant BW viruses de novo and the potential for altering the pathogenic properties of viruses for nefarious purposes.¹⁵

“[D]efined infectious sequences are documented and methods have been reported in the literature. *Infectious genomes of many Class IV viruses*

⁹ <https://dspace.mit.edu/handle/1721.1/39141>.

¹⁰ <https://dspace.mit.edu/handle/1721.1/39658>

¹¹ Dr. Baric and the U.S. Department of Defense spent over \$45 million in amplifying the toxicity of CoV and its chimeric derivatives. For NIH grants to Baric, 1991 – 2021, see <https://grantome.com/search?q=baric>.

¹² See *infra*, fn 54.

¹³ See *infra*, fn 53.

¹⁴ “Giving an unequivocal definition of *synthetic biology* is challenging, even for the various actors in the field. Rather than constituting a strictly defined field, *synthetic biology may be best described as an engineering-related approach to rationally design and construct biological compounds, functions and organisms not found in nature, or to redesign existing biological parts and systems to carry out new functions.*” König, Harald et al. “Synthetic genomics and synthetic biology applications between hopes and concerns.” *Current genomics* vol. 14,1 (2013): 11-24. doi:10.2174/1389202911314010003; www.ncbi.nlm.nih.gov/pmc/articles/PMC3580775/.

¹⁵ Baric RS. 2006, Univ. North Carolina at Chapel Hill, *Synthetic Viral Genomics. In: Working Papers for Synthetic Genomics: Risks and Benefits for Science and Society*, pp. 35-81. Garfinkel MS, Endy D, Epstein GL, Friedman RM, editors. 2007, p. 36.

<https://dspace.mit.edu/bitstream/handle/1721.1/39652/Baric%20Synthetic%20Viral%20Genomics.pdf>.

[including coronavirus] could be purchased and the need for trained staff becomes minimized. Today, ... a coronavirus genome [could be purchased] for less than \$40,000.... [I]t is conceivable that technical advances over the next decade may even render large viral genomes commercially available for use by legitimate researchers, but perhaps also by bioterrorists.^{16,17}

“[U]sing the expanding database of genomic sequences and identified virulence genes, the *benign viral genome could be modified into more lethal combinations for nefarious use.*¹⁸ (Emphasis added.)

“*Understanding the Risk of Bat Coronavirus Emergence Novel zoonotic, bat-origin CoVs are a significant threat to global health and food security.* In a previous R01 we found that bats in southern China harbor an extraordinary diversity of *SARSr-CoVs* [sic], *some of which can use human ACE2 to enter cells*, infect humanized mouse models causing SARS-like illness, and evade available therapies or vaccines....at one site diverse *SARSr-CoVs* [sic] exist that contain every genetic element of the SARS-CoV genome, and identified serological evidence of human exposure among people living nearby.”¹⁹ (Emphasis added.)

¹⁶ Id. at 62. <https://dspace.mit.edu/bitstream/handle/1721.1/39652/Baric%20Synthetic%20Viral%20Genomics.pdf>; see also *infra* fn. 15 regarding the use of synthetic, chimeric organisms in bioterrorism activities.

¹⁷ See *infra*, fn. 25, Peter Daszak, video clip regarding engineering spike protein to create “real killers” from coronavirus.


¹⁸ Id. at 66. Baric’s research history with coronavirus and synthetic chimeric creations is storied. For example, see Yount B, Roberts RS, Lindesmith L, Baric RS., [Rewiring the severe acute respiratory syndrome coronavirus \(SARS-CoV\) transcription circuit: engineering a recombination-resistant genome](#). Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12546-51. doi: 10.1073/pnas.0605438103. Epub 2006 Aug 4. PMID: 16891412; PMCID: PMC1531645. The abstract of the article reads as follows: “*Live virus vaccines provide significant protection against many detrimental human and animal diseases, but reversion to virulence by mutation and recombination has reduced appeal.* Using severe acute respiratory syndrome coronavirus as a model, we engineered a different transcription regulatory circuit and isolated recombinant viruses. The transcription network allowed for efficient expression of the viral transcripts and proteins, and the recombinant viruses replicated to WT levels. Recombinant genomes were then constructed that contained mixtures of the WT and mutant regulatory circuits, reflecting recombinant viruses that *might* occur in nature. Although viable viruses could readily be isolated from WT and recombinant genomes containing homogeneous transcription circuits, *chimeras that contained mixed regulatory networks were invariably lethal, because viable chimeric viruses were not isolated.* Mechanistically, mixed regulatory circuits promoted inefficient subgenomic transcription from inappropriate start sites, resulting in truncated ORFs and effectively minimize viral structural protein expression. Engineering regulatory transcription circuits of intercommunicating alleles successfully introduces genetic traps into a viral genome that are lethal in RNA recombinant progeny viruses. See also, Becker M M, Graham R L, Donaldson E F, Rockx B, Sims A C, Sheahan T, Pickles R J, Corti D, Johnston R E, Baric R S, Denison M R., [Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice](#). Proc. Natl. Acad. Sci. USA. 2008;105:19944–19949.

¹⁹ <https://grantome.com/grant/NIH/R01-AI110964-06>; see also König, Harald et al. “Synthetic genomics and synthetic biology applications between hopes and concerns.” *Current genomics* vol. 14,1 (2013): 11-24. doi:10.2174/1389202911314010003. “The generation of *chimeric antigens* exemplifies a relatively straightforward approach to *construct novel diagnosis tools for pathogens* (e.g. Lyme disease) involving DNA-synthesis. Rather complex DNA-synthesis and genome-assembly techniques have been used to generate entire viral genomes and to address the etiology and pathogenicity mechanisms of corresponding viruses, including the viruses that caused the

In 2005, the Defense Advanced Research Projects Agency (DARPA) and Massachusetts Institute of Technology Research and Engineering (MITRE) hosted a conference in which the intentions of the U.S. Department of Defense were explicit regarding the use of Baric's chimeric research.²⁰

Figure 9. PCA Technique. Synthetic Reconstruction of Exotic SARS-CoV Spike Glycoproteins.

Synthetic S glycoproteins are synthesized and inserted into the SARS-CoV molecular clone; allowing for recovery of recombinant viruses encoding zoonotic S glycoproteins.



1918 influenza pandemic or that are responsible for SARS. Similarly, *such synthetic genomics technology can be exploited to introduce hundreds of base-pair changes in codon pairs in order to produce live attenuated viral vaccines by means of computer-aided rational design...* Though much biotechnology knowledge and expertise has likely already proliferated globally, *recent studies into various assessments on bioscience research and bioterrorism suggest that the attractiveness and feasibility of “synthetic” solutions for bioterrorist use may have to be reconsidered, especially when compared to available “low-tech” solutions.* Still recent experiments, involving directed evolution and genetic-engineering, into the airborne transmission of the deadly bird-flu virus H5N1 in ferrets (a model to study influenza transmission in humans) have revigorated debates about conditions for publication of biosecurity-sensitive data. (ii) As regards the other threat that is more specifically linked to the onset of synthetic biology, it may become more difficult, or even impossible, to assess the risks of extensively genetically modified or (putative) entirely “synthetic” future organisms, based on similarities with donor and recipient organisms. This issue may become more significant as the areas of synthetic genomics and synthetic biology progress and it remains to be seen whether synthetic biology-derived containment strategies (including xenobiotic mechanisms) can contribute to solve biosafety issues in future. Risk assessment may thus need to shift from prediction-based assessment to (more) real testing.” (Citations omitted.)

²⁰ Becker M M, Graham R L, Donaldson E F, Rockx B, Sims A C, Sheahan T, Pickles R J, Corti D, Johnston R E, Baric R S, Denison M R., Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. *Proc. Natl. Acad. Sci. USA.* 2008;105:19944–19949 at p. 59.

ACT I, SCENE III

- Time and place: 4 May 2009, WHO, Geneva, Switzerland
- Event: WHO, one month before declaring the H1N1 influenza outbreak a pandemic, changed its definition of the term “Pandemic” on its website, altering the definition from a 6-year use
- Purpose: WHO broadens the definition of the term “pandemic” to apply to any virus to which humans have no immunity, regardless of any other metric
- Actor: WHO
- Statements: “Since 2003, the top of the WHO Pandemic Preparedness homepage has contained the following statement: ‘An influenza pandemic occurs when a new influenza virus appears against which the human population has no immunity, resulting in several simultaneous epidemics worldwide with enormous numbers of deaths and illness.’ However, on 4 May 2009, scarcely one month before the H1N1 pandemic was declared, the web page was altered in response to a query from a CNN reporter. The phrase ‘enormous numbers of deaths and illness had been removed and the revised web page simply read as follows: “*An influenza pandemic may occur when a new influenza virus appears against which the human population has no immunity.*” Months later, the Council of Europe would cite this alteration as evidence that WHO changed its definition of pandemic influenza to enable it to declare a pandemic without having to demonstrate the intensity of the disease caused by the H1N1 virus.²¹
- “[C]oncern over ties between WHO advisers and industry fuelled [sic] suspicion about the independence and appropriateness of the decisions made at the national and international levels.
- “Central to this debate has been the question of whether H1N1 influenza should have been labelled a ‘pandemic’ at all. The Council of Europe voiced serious concerns that the declaration of a pandemic became possible only after WHO changed its definition of pandemic influenza.”²² (Citations omitted.) (Emphasis added.)

²¹ *The elusive definition of pandemic influenza*, Peter Doshi, Bulletin of the World Health Organization, p. 532; Bull World Health Organ 2011;89:532–538 | doi:10.2471/BLT.11.086173.

²² Id.

ACT II, SCENE I

Time and place:	May 2011, WHO, World Health Assembly (WHA), and UN, Geneva, Switzerland
Event:	64 th WHA ²³
Purpose:	Work begins on draft of draft global vaccine action plan, ²⁴ builds on the success of the Global Immunization Vision and Strategy, 2006–2015, adopt and implement the Pandemic Influenza Preparedness Framework, including improving and strengthening the WHO global influenza surveillance and response system (“WHO GISRS”), ²⁵ Launch Decade of Vaccines 2011-2020 (DOV)
Actors:	WHO, WHA, UNICEF, UN, GAVI, others
Statement:	“ <i>Immunization</i> is, and should be recognized as, a core component of the <i>human right</i> to health and an individual, community and governmental <i>responsibility</i> . . . Governments and elected officials are responsible for putting in place necessary legislation and budget allocations.” ²⁶ (Emphasis added.)

²³ Microsoft Word - A64_R1_COV+PRELIMS-en.docx (who.int)

²⁴ https://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_22-en.pdf. *See fn 1*, “See documents A64/14 and WHA64/2011/REC/2, summary records of the sixth meeting, section 2, the seventh meeting and the eighth meeting, section 2.”

²⁵ *Id.* at Annex 2, p. 76.

²⁶ Draft Global Vaccine Action Plan, paras. 3 and 35. https://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_22-en.pdf.

ACT II, SCENE II

Time and place:	May 11, 2012, New York
Event:	65 th WHA
Purpose:	Review and Adoption of the Draft Global Vaccination Plan
Actors:	WHO, WHA, UNICEF, UN, and others
Statement:	<p>“The last century was . . . the century of treatment. . . <i>This century promises to be the century of vaccines.</i> . . Ensuring that the vision for the Decade of Vaccines becomes a reality is a powerful step in that direction.”²⁷</p> <p>“Now is the time for showing commitment to achieving the full potential of immunization. The collective recognition of this opportunity <i>has led the global health community to call for a Decade of Vaccines</i>, in line with the requests made in resolution WHA61.15 on the global immunization strategy.</p> <p>“The vision for the Decade of Vaccines (2011–2020) is of a world in which <i>all individuals and communities enjoy lives free from vaccine-preventable diseases. The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefit of immunization to all people</i>, regardless of where they are born, who they are or where they live.”²⁸ (Emphasis added.)</p>

²⁷ Id. para. 6.

²⁸ Id. at para. 4.

ACT III, SCENE I

Time and place:	March 27, 2015, Washington D.C.
Event:	Forum on Medical and Public Health Preparedness for Catastrophic Events
Purpose:	Lament the world’s reluctance to adopt the “Century of the Vaccine Plan” and Legislatively Enforceable Immunizations
Actors:	Peter Daszak, president of EcoHealth Alliance ²⁹
Statement:	“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs (medical countermeasures) such as a pan-influenza or <i>pan-coronavirus vaccine</i> . <i>A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process,</i> ’ Daszak stated.” ³⁰ (Emphasis added.)

²⁹ [Developing MCMs for Coronaviruses - Rapid Medical Countermeasure Response to Infectious Diseases - NCBI Bookshelf \(nih.gov\)](#).

³⁰ Id.

ACT III, SCENE II

Time and place:	February 23, 2016, New York, NY
The event:	New York Academy of Medicine
Purpose:	Describing the creation of chimeric coronavirus
Actors:	Peter Daszak, President EcoHealth Alliance
Statement:	“Some of these viruses will be killers, some of them won’t. How we work that out from a viral sequence is not straightforward. So, as an example, first of all, <i>we are only looking at viral families that include those that have gone into people from animals</i> . So, now we narrowed it down straight-away. <i>Then, when you get a sequence of the virus, and it looks like a relative of the known nasty pathogen, just like we did SARS – we found other coronaviruses in bats – a whole host of them. Some of them looked very similar to SARS</i> . So, <i>we sequenced the spike protein, the protein that attaches to cells</i> . Then we, <i>well I didn’t do this work but my colleagues in China did the work, you create pseudo-particles, you insert spike proteins from those viruses, see if it binds to human cells</i> . Each step of this, you move closer and closer to this virus that could really become pathogenic in people. So, you narrow down the field. You reduce cost and end up with a small number of viruses that really do look like killers. ” ³¹ (Emphasis added.)

³¹ [https:// www.c-span.org/video/?c4966587/user-clip-peter-daszak-describes-colleagues-china-manipulating-viruses](https://www.c-span.org/video/?c4966587/user-clip-peter-daszak-describes-colleagues-china-manipulating-viruses).

ACT III, SCENE II

Time and place:	January 17, 2017, Georgetown University
The event:	Pandemic Preparedness in the Next US Presidential Administration
Purpose:	Create demand for vaccines. DOV is off track, need additional push to market and sell the “Century of Vaccines” Plan to the global public.
Actor:	Dr. Anthony Fauci
The Statement:	“If there’s one message that I want to leave with you today based on my experience, it is that <i>there is no question that there will be a challenge to the coming administration in the arena of infectious diseases. . .</i> No matter what, history has told us definitively that [outbreaks] will happen. It is a perpetual challenge. It is not going to go away. The thing <i>we’re extraordinarily confident about is that we are going to see this in the next few years.</i> ” ³² (Emphasis added.)

³² Global Health Experts Advise Advance Planning for Inevitable Pandemic | Georgetown University Medical Center | Georgetown University.

ACT IV, SCENE I

Time and place:	October 18, 2019, New York, NY
The Event:	Event 201
The Purpose:	Simulate a global pandemic using a coronavirus ³³
The Actors:	Open Philanthropy (Facebook’s Dustin Moskovitz), the Bill & Melinda Gates Foundation, the World Economic Forum, and Johns Hopkins University, et. al. ³⁴
The Statement:	“For the scenario, <i>we modeled a fictional coronavirus pandemic</i> , but we explicitly stated that it was not a prediction. Instead, the exercise served to highlight preparedness and response challenges that would likely arise in <i>a very severe pandemic.</i> ” ³⁵ (Emphasis added.)

³³ [Event 201, a pandemic exercise to illustrate preparedness efforts \(centerforhealthsecurity.org\);
https://centerforhealthsecurity.org/event201/.](https://centerforhealthsecurity.org/event201/)

³⁴ Id.

³⁵ [Statement about nCoV and our pandemic exercise \(centerforhealthsecurity.org\)](#)

ACT IV, SCENE II - FINALE

Time and Place:	January 20, 2020, New York, NY
The Event:	WHO Global Announcement
The Purpose:	Incite global fear
The Actor:	WHO
The Statements:	<p>“Chinese authorities have made a preliminary determination of a novel (or new) coronavirus, identified in a hospitalized person with pneumonia in Wuhan.</p> <p>“Chinese investigators conducted gene sequencing of the virus, using an isolate from one positive patient sample. Preliminary identification of a novel virus in a short period of time is a notable achievement and demonstrates China’s increased capacity to manage new outbreaks.</p> <p>“According to Chinese authorities, the virus in question can cause severe illness in some patients and does not transmit readily between people.”³⁶</p>

³⁶ [WHO Statement regarding cluster of pneumonia cases in Wuhan, China](#)

THE TRUE
NARRATIVE:
UNLEASHING
A BIOWEAPON
ON AN UNSUSPECTING
GLOBAL POPULATION
... AS A HUMAN
RIGHT

GLOBAL VACCINE ACTION PLAN: THE TRAP IS LAID

In February 2013, a final draft of a global plan to inflict the global population with a bioweapon³⁷ was polished, signed, and published.³⁸ Its purpose was criminal, nefarious, and driven by greed – “commercial interests.” Entitled “*Global Vaccine Action Plan 2011-2020*” (GVAP), it carried the imprimatur and signatures of the following cast of characters and organizations:

- Dr. Seth Berkley, Chief Executive Officer *GAVI Alliance*;
- Dr. Margaret Chan, Director General, *World Health Organization (WHO)*;
- Dr. Christopher Elias, President, Global Development Program, *Bill & Melinda Gates Foundation*;
- Dr. Anthony Fauci, Director, *US National Institute of Allergies, and Infectious Diseases (NIAID)*;
- Mr. Anthony Lake, Executive Director, *United Nations Children’s Fund (UNICEF)*; and
- Ms. Joy Phumaphi, Executive Secretary, *African Leaders Malaria Alliance*.

GLOBAL STRATEGIC FRAMEWORK: EVERYONE WILL BE IMMUNIZED

Spearheaded by Chris Elias of the Bill & Melinda Gates Foundation and Dr. Anthony Fauci of the US National Institute of Allergies and Infectious Diseases, this self-appointed group declared the fundamental commercial dictum: “to extend immunization to everyone.”³⁹

THE DECADES OF VACCINES

The groundwork for GVAP had been assiduously laid for several years by unelected and unaccountable powers. In 2005, the World Health Assembly (WHA), under the auspices of the WHO, launched the Global Immunization Vision and Strategy, 2006–2015, “the first 10-year *strategic framework to realize the potential of immunization*.”⁴⁰ In May 2011, five years before the strategic decade was completed, the WHA Secretariat pursued discussions of a new plan for

³⁷ *Draft Global Vaccine Action Plan*, 65th World Health Assembly, 11 May 2012, Introduction, para. 3, https://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_22-en.pdf. “Immunization is, and should be recognized as, a core component of the human right to health and an individual, community and governmental responsibility.... As part of a comprehensive package of interventions for disease prevention and control, vaccines and immunization are an essential investment in a country’s – indeed, in the world’s – future.”

³⁸ *Global Vaccine Plan 2011-2020*. <https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020>.

³⁹ *Global Vaccine Action Plan*, p. 6. See <https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020>.

⁴⁰ Draft global vaccine action plan, p.1 para. 2. https://app.who.int/iris/bitstream/handle/10665/69146/WHO_IVB_05.05.pdf; or apps.who.int/gb/ebwha/pdf_files/WHA65/A65_22-en.pdf

the years from 2011-2020: the *Decade of Vaccines (DOV)*.⁴¹ The WHA and WHO “welcomed” those discussions and attendant plans.⁴²

Ironically, in December of this same year (2005), the Public Readiness and Emergency Preparedness Act⁴³ (the Act) was signed into law by President George W. Bush.⁴⁴ The Act included targeted liability protections for “pandemic and epidemic products and security countermeasures.”⁴⁵ In short, vaccine manufacturers were “immune from suit and liability under Federal and State law with respect to all claims for loss caused by ... an individual of a covered countermeasure,” including death, physical, mental, or emotional injury, illness, or disability,” as well as loss or damage to property, including business interruption loss.⁴⁶ Clearly, all risks and costs of claiming the “human right” in the form of an immunization, or being coerced to receive it by government force, was to be borne solely by the individual human into whom “countermeasure” was injected. Such was the nature of the “national legislation” that the Decade of Vaccine plans had portended.⁴⁷

⁴¹ Id. The phrase or title “The Decade of Vaccines” appears twenty-one times throughout the entirety of the 39 page document, Draft global vaccine action plan.

⁴² Id. p.1 para. 1.

⁴³ 42 USC 201 et seq.

⁴⁴ President’s Statement on Signing of H.R. 2863, the “Department of Defense, Emergency Supplemental Appropriations to Address Hurricanes in the Gulf of Mexico, and Pandemic Influenza Act, 2006; georgewbush-whitehouse.archives.gov/news/releases/2005/12/20051230-8.html#:~:text=into%20law%20H.R.-2863,%20the%20"Department%20of%20Defense,%20Emergency%20Supplemental%20Appropriations%20to,and%20protect%20Americans%20from%20a; See 42 USC 201 et seq., <https://www.congress.gov/109/plaws/publ148/PLAW-109publ148.pdf>.

⁴⁵ Id.

⁴⁶ Id. The statute states in relevant part: “SEC. 319F-3. TARGETED LIABILITY PROTECTIONS FOR PANDEMIC AND EPIDEMIC PRODUCTS AND SECURITY COUNTERMEASURES. (a) LIABILITY PROTECTIONS.— (1) IN GENERAL.—Subject to the other provisions of this section, *a covered person shall be immune from suit and liability under Federal and State law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or the use by an individual of a covered countermeasure if a declaration under subsection (b) has been issued with respect to such countermeasure.* (2) SCOPE OF CLAIMS FOR LOSS.— (A) LOSS.—For purposes of this section, the term ‘loss’ means any type of loss, including— (i) death; (ii) physical, mental, or emotional injury, illness, disability, or condition; (iii) fear of physical, mental, or emotional injury, illness, disability, or condition, including any need for medical monitoring; and (iv) loss of or damage to property, including business interruption loss. Each of clauses (i) through (iv) applies without regard to the date of the occurrence, presentation, or discovery of the loss described in the clause. (B) SCOPE.—The immunity under paragraph (1) applies to any claim for loss that has a causal relationship with the administration to or use by an individual of a covered countermeasure, including a causal relationship with the design, development, clinical testing or investigation, manufacture, labeling, distribution, formulation, packaging, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, or use of such countermeasure. (Emphasis added.)

⁴⁷ See *supra* fn. 22 and *infra* fn 47.

IMMUNIZATION, THE NEW HUMAN RIGHT, WORLD SAVIOR, AND CRIME

One year later, on 11 May 2012, the “Draft global vaccination action plan” (the “Draft”) was proposed.⁴⁸ The draft included an auspicious, gratuitous, and self-interested fiat creation: immunization as a new human right. The WHA spelled it out as follows:

*“Immunization is, and should be recognized as, a core component of the human right to health and an individual, community and governmental responsibility.”*⁴⁹
(Emphasis added.)

Thus, the WHO and WHA created, by an unknown and unrecognized authority, a new human right with a severe corresponding responsibility. Doubtless, this new human right would require a global bureaucracy with all the trappings. Moreover, the authors of the Draft included an exhaustive list of the “stakeholders” necessary to implement this new global human right along with their exhaustive responsibilities.⁵⁰ The Draft continues:

*“As part of a comprehensive package of interventions for disease prevention and control, vaccines and immunization are an essential investment in a country’s – indeed, in the world’s – future.”*⁵¹ (Emphasis added.)

THE CENTURY OF THE VACCINES

Laying the foundations for the investment in this, the world’s new future, the Draft also identifies the method by which the authors’ prime commercial directive was to be achieved -- with this ominous statement:

*“The last century was, in many respects, the century of treatment. . . . This century promises to be the century of vaccines[.] Ensuring that the vision for the Decade of Vaccines becomes a reality is a powerful step in that direction.”*⁵² (Emphasis added.)

Hence, the WHA, with the WHO as its midwife, gave birth to a sainted creature to which all knees would bow and every tongue confess allegiance and fealty, i.e., the sacred and all-powerful

⁴⁸ Id.

⁴⁹ Id. p.1, para. 3.

⁵⁰ Id. Annex 2, pp. 35-39. Stakeholders identified in the Draft include the following: Individuals and communities, governments, health professionals, academia, manufacturers, global agencies (such as WHO, UNICEF, the World Bank, regional development banks and the GAVI Alliance), development partners, civil society, media, and the private sector.

⁵¹ Id.

⁵² Id. p. 2, p. 6.

vaccines and immunizations, the “essential investments,” that would save the world for the next one hundred years.

Yet, the WHO and WHA were not the only organizations positioning “vaccines” as saviors of humanity’s future. Indeed, an entire army of organizations would be needed to implement the global plans. A short list of that phalanx of holy sister organizations includes the following:

- the United Nations Millennium Declaration;
- the United Nations World Summit for Children;
- the United Nations General Assembly Special Session on Children;
- the United Nations Secretary-General’s Global Strategy for Women’s and Children’s Health;
- the GAVI Alliance;
- the Global Polio Eradication Initiative;
- the Measles Initiative;
- UNICEF’s vaccine procurement services; and
- PAHO’s Revolving Fund for Vaccine Procurement.

NEW LAWS: ENFORCING THE INDIVIDUAL RIGHT AND THE INDIVIDUAL RESPONSIBILITY

To support their “vaccine as a human right and responsibility” imperative, Elias, Fauci, WHO, WHA, and others also identified the requirement of national legislation. Certainly, this human right needed enforcement of government law to ensure all would receive the “right,” whether they wanted it or not. After all, this new human right was also a “responsibility.” Additionally, for those who need some extra persuasion, “technical experts” and “champions of immunization” would be recruited to guarantee compliance with their global immunization mandates:

*“National legislation, policies and resource allocation decisions should be informed by credible and current evidence regarding the direct and indirect impact of immunization. . . . Collaboration between, on the one hand, technical experts who generate the evidence and, on the other, the champions of immunization who construct context-specific messages . . . can unequivocally articulate the value of immunization[.]”*⁵³ (Emphasis added.)

Reaching even further, the Draft authors asserted that “[l]essons on vaccines and immunization should be included in the primary school education curriculum”⁵⁴ of all member countries.

⁵³ Id. pp. 8-9, para. 33.

⁵⁴ Id. p. 11, para. 38.

In short, declaring vaccination an essential “human right,” they spent the decade seeking to develop and deploy a “universal vaccination.” In the end, however, their efforts for global traction failed. No one wanted what they were selling.

THE RESET

Bemoaning their failure before Congress and the World Health Organization, they complained that the public was reticent to accept their “universal” vaccines and even more reluctant to embrace their global control plan dressed in the sheep’s clothing of “human rights.” Possibly informed by the obvious and compelling failure of the influenza “vaccines” that failed to disrupt annual flu seasons, the public was not falling for their Decade of the Vaccine obsession.

In 2015, Dr. Peter Daszak, president of EcoHealth Alliance (veterinarian and NIAID pandemic engineer), with laboratories at the University of North Carolina at Chapel Hill, lamented:

“...until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. *A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process,*” Daszak stated.⁵⁵ (Emphasis added.)

THE FAUCIAN BARGAIN

Less than two years later, on January 12, 2017, and as if on cue, Georgetown University hosted “Pandemic Preparedness in the Next US Presidential Administration,” a gathering of global health experts “from academia, government and advocacy.” There, Fauci and other global health leaders, just days before President Trump’s inauguration, warned the incoming Trump administration to plan for their global pandemic. Specifically, Fauci prophesied with certainty that a “‘surprise outbreak’ would occur during the Trump administration.”⁵⁶

“‘If there’s one message that I want to leave with you today based on my experience, it is that *there is no question that there will be a challenge to the coming administration in the arena of infectious diseases,*” Fauci said.⁵⁷ (Emphasis added.)

⁵⁵ <https://www.ncbi.nlm.nih.gov/books/NBK349040/>

⁵⁶ [Dr. Fauci Warned In 2017 Of ‘Surprise Outbreak’ During Trump Administration | HuffPost Latest News](#)

⁵⁷ [Global Health Experts Advise Advance Planning for Inevitable Pandemic | Georgetown University Medical Center | Georgetown University.](#)

One is compelled to ask oneself, from where did Fauci obtain his certitude of an oncoming infectious disease outbreak? Indeed, since his appointment in 1984 to lead the NIAID, he had never had to confront the type or scale of infectious disease catastrophe of which he was so strongly forewarning.

“No matter what, history has told us definitively that [outbreaks] will happen,’ he said. ‘It is a perpetual challenge. It is not going to go away. The thing *we are extraordinarily confident about is that we are going to see this in the next few years.*’”⁵⁸ (Emphasis added.)

What did Fauci know about the “surprise outbreak” of an infectious disease “in the next few years?” It begs credulity that WHO announced “a mysterious coronavirus-related pneumonia in Wuhan, China” on January 20, 2020, nearly three years to the day of Fauci’s fortune-telling.⁵⁹

In fact, Fauci and this cadre had missed the opportunity to leverage the deadly flu season of 2018. Consequently, Fauci, Elias, and Daszak announced that they would construct a scenario to mandate that ALL countries respond to a “lethal respiratory pathogen.” These criminal conspirators put humanity on a collision course with a manufactured “pandemic” to create the vaccine dependency program that they had designed in 2005 under the Decade of Vaccines program, and the broader “Century of Vaccines” program launched in 2015. They published their plans in September 2019, a mere three months before the surprise outbreak:

“A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in development of innovative vaccine and therapeutics, surge manufacturing capacity, broad-spectrum antivirals, and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing sequences of any new pathogen for public health purposes, along with the means to share limited medical countermeasures across countries.”⁶⁰

“Progress indicator(s) by September 2020.

“Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad-spectrum antivirals and targeted therapeutics. WHO and Member States develop options for standard

⁵⁸ [Dr. Fauci Warned In 2017 Of ‘Surprise Outbreak’ During Trump Administration | HuffPost Latest News.](#)

⁵⁹ “*WHO declares coronavirus a pandemic, urges aggressive action.*” AP News, March 11, 2020. [WHO declares coronavirus a pandemic, urges aggressive action | AP News.](#)

⁶⁰ [A World at Risk: Annual report on global preparedness for health emergencies - Global Preparedness Monitoring Board \[EN/AR/RU/ZH\] - World | ReliefWeb,](#) Executive Summary: Actions for Leaders to Take.

procedures and timelines for sharing of sequence data, specimens and medical countermeasures for pathogens other than influenza.”⁶¹

THE PANDEMIC SIMULATION

One month later, on October 18, 2019, they announced that they would use SARS Coronavirus as a “desktop” simulation during the Event 201 exercise funded by Open Philanthropy (Facebook’s Dustin Moskovitz) and hosted by the Bill & Melinda Gates Foundation, the World Economic Forum, and Johns Hopkins University.⁶²

THE PANDEMIC CREATION: A DISEASE WITHOUT A DIAGNOSIS

COVID-19, the first “disease” to have NO diagnostic test to measure its existence, was a series of symptoms aggregated to form an influenza-like illness to create the illusion of a pandemic. Now discredited, the RT-PCR test (amplified to cycles that could simulate any nucleic acid sequence) was used to create the illusion of infection and spread fear around the world. And all of this was to force the public adoption of a novel mRNA “vaccine” which, by the FDA’s own classification is a gene therapy⁶³ – not the promised “human right” public health immunization.

Now, over one year later it has become self-evident that the “vaccination” terminology was adopted for two reasons: (1) branding purposes (including the attempt to secure immunity shields for manufacturers); and (2) to coerce the population into accepting an experimental, dangerous, gene therapy technology.

Rather than the promised immunizations that would spell the salvation of the world’s future in this, the Century of the Vaccine, the injected are getting sick. The injected are dying “of COVID-19.” There is NO evidence that the injections have disrupted transmission, as the recent “Omicron variant” has now made abundantly clear.

THIS WAS NEVER ABOUT PUBLIC HEALTH!

⁶¹ *A World at Risk*, Global Preparedness Monitoring Board, https://reliefweb.int/sites/reliefweb.int/files/resources/GPMB_annualreport_2019.pdf, Executive Summary p. VI, Required Actions, p. 20.

⁶² [Event 201, a pandemic exercise to illustrate preparedness efforts \(centerforhealthsecurity.org\)](https://www.cdc.gov/media/releases/2019/s1018-event201.html).

⁶³ <https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna-20200630.htm>.

THE ORGANIZED CRIMINAL RACKET AND THEIR FELONIES

The forensic path and recorded documentary history detailed here was never about public health. Rather, it was, and has always been, an organized crime racket to coerce the public's adoption of a novel technology that has NEVER been shown to be safe or effective under the definitions of the FDA, the Federal Trade Commission's Deceptive Medical Practices standard, or under any other statutory criteria.

It is long past time to hold the criminals accountable for the following crimes:

- Domestic and International Terrorism;⁶⁴
- Deceptive Medical Practices;⁶⁵
- Reckless Endangerment and Homicide;⁶⁶
- Racketeering and Anti-trust collusion;⁶⁷ and,

⁶⁴ 18 USC 2339. Harboring and Concealing Terrorists. "(a) Whoever harbors or conceals any person who he knows, or has reasonable grounds to believe, has committed, or is about to commit, an offense under section 32 (relating to destruction of aircraft or aircraft facilities), section 175 (relating to biological weapons), section 229 (relating to chemical weapons), section 831 (relating to nuclear materials), paragraph (2) or (3) of section 844(f) (relating to arson and bombing of government property risking or causing injury or death), section 1366(a) (relating to the destruction of an energy facility), section 2280 (relating to violence against maritime navigation), section 2332a (relating to weapons of mass destruction), or section 2332b (relating to acts of terrorism transcending national boundaries) of this title, section 236(a) (relating to sabotage of nuclear facilities or fuel) of the Atomic Energy Act of 1954 (42 U.S.C. 2284(a)), or section 46502 (relating to aircraft piracy) of title 49, shall be fined under this title or imprisoned not more than ten years, or both.

(b) A violation of this section may be prosecuted in any Federal judicial district in which the underlying offense was committed, or in any other Federal judicial district as provided by law.

⁶⁵ 15 USC 45(c).

⁶⁶ 18 USC 51.

⁶⁷ 15 USC §1. Trusts, etc., in restraint of trade illegal; penalty

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding \$100,000,000 if a corporation, or, if any other person, \$1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

15 USC §8. Trusts in restraint of import trade illegal; penalty

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to

- Biological Weapons Construction and Deployment.⁶⁸

I have been the solitary voice calling for this accountability since the inception of this scheme. I am now leading efforts to litigate all the matters identified above, as well as hold the conspiring commercial interests liable for tax and securities fraud. In the former, each manufacturer has misused the In Process Research and Experimentation Tax Credit, misrepresenting sponsored research as qualified exemptions. In the latter, each manufacturer has violated that Bayh-Dole Act and has thereby misrepresented proprietary interests to their shareholders in violation of SEC laws.

The time to act is now. As a national and global citizenry, we must stand to protect and defend humanity against the largest criminal enterprise in world history.

violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the United States such person shall be fined in a sum not less than \$100 and not exceeding \$5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

⁶⁸ 18 USC §175. Prohibitions with respect to biological weapons

(a) In General.-Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses *any biological agent, toxin, or delivery system for use as a weapon*, or *knowingly assists a foreign state or any organization to do so, or attempts, threatens, or conspires to do the same*, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States.

(b) Additional Offense. -Whoever *knowingly possesses any biological agent, toxin, or delivery system of a type or in a quantity that, under the circumstances, is not reasonably justified by a prophylactic, protective, bona fide research, or other peaceful purpose*, shall be fined under this title, imprisoned not more than 10 years, or both. In this subsection, the terms "biological agent" and "toxin" do not encompass any biological agent or toxin that is in its naturally occurring environment, if the biological agent or toxin has not been cultivated, collected, or otherwise extracted from its natural source.

(c) Definition. -For purposes of this section, the term "*for use as a weapon*" includes the development, production, transfer, acquisition, retention, or possession of any biological agent, toxin, or delivery system for other than *prophylactic, protective, bona fide research, or other peaceful purposes*. (Italics added.)

SCHEDULE I

Patent Filing Records Associated with SARS CoV, SARS CoV2, Spike Protein, and ACE2 Binding



The following data is being made publicly available for the Commons by M·CAM International LLC based on a series of reviews of patent literature derived from references found in:

A novel bat coronavirus reveals natural insertions at the S1/S2 2 cleavage site of the Spike protein and a possible recombinant 3 origin of HCoV-19 4 Hong Zhou^{1,8}, Xing Chen^{2,8}, Tao Hu^{1,8}, Juan Li^{1,8}, Hao Song³, Yanran Liu¹, Peihan Wang^{1 5}, Di Liu⁴, Jing Yang⁵, Edward C. Holmes⁶, Alice C. Hughes^{2,*}, Yuhai Bi^{5,*}, Weifeng Shi^{1,7,*}

The Proximal Origin of SARS-CoV-2 Kristian G. Andersen^{1,2*}, Andrew Rambaut³, W. Ian Lipkin⁴, Edward C. Holmes⁵ & Robert F. Garry^{6,7}

And sequences leading to the reporting of genomic epidemiology at <https://nextstrain.org/ncov>

Polybasic cleavage site for SARS CoV with novel spike protein and ACE2 RBD

US9834595	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08 29-Oct-15 5-Dec-17
US9193780	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08 5-Jun-09 24-Nov-15
US20190077847 14-Mar-19	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5-Jun-08 17-Oct-17 14-Mar-19
US20160152693 2-Jun-16	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5-Jun-08 29-Oct-15 2-Jun-16
US10550174	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08 17-Oct-17 4-Feb-20
US10407492	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08 17-Oct-17 10-Sep-19

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434 · 979 · 7240



O-linked glycans and SARS CoV Spike Protein Data disclosures

Document number	Title	Assignee name	Priority date File date Issue date
US9644180	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 12-Jun-15 9-May-17
US8741311	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09 26-Mar-10 3-Jun-14
US8735416	Antiviral therapies	Technische Universitaet Carolo-Wilhelmina zu Braunschweig	21-Sep-05 23-Apr-12 27-May-14
US7604960	Transient protein expression methods	Cruceell Holland B.V.	15-Apr-99 1-Jun-07 20-Oct-09
US20200046826 13-Feb-20	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09 4-Jun-19 13-Feb-20
US20200040042 6-Feb-20	CHIMERIC MOLECULES AND USES THEREOF	Not Available	30-Mar-17 29-Mar-18 6-Feb-20
US20200002674 2-Jan-20	ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE	Not Available	18-Nov-13 16-Sep-19 2-Jan-20
US20190376034 12-Dec-19	PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF	Not Available	18-Nov-13 23-Aug-19 12-Dec-19
US20190316091 17-Oct-19	ERYTHROID CELLS COMPRISING ARGINASE	Not Available	18-Nov-13 30-May-19 17-Oct-19
US20190316090 17-Oct-19	ERYTHROID CELLS COMPRISING ARGININE DEIMINASE	RUBIUS THERAPEUTICS, INC.	18-Nov-13 30-May-19 17-Oct-19
US20190316089 17-Oct-19	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 10-May-19 17-Oct-19
US20190309262 10-Oct-19	ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE	Not Available	18-Nov-13 4-Jun-19 10-Oct-19
US20190309261 10-Oct-19	ERYTHROID CELLS COMPRISING LYSINE OXIDASE	Not Available	18-Nov-13 4-Jun-19 10-Oct-19
US20190264177 29-Aug-19	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 10-May-19 29-Aug-19
US20190263934 29-Aug-19	FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFE	Not Available	26-Jan-18 25-Jan-19 29-Aug-19
US20190144827 16-May-19	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	RUBIUS THERAPEUTICS, INC.	18-Nov-13 19-Nov-18 16-May-19

ANIMATE VALUE™



US20180265847 20-Sep-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 29-Mar-18 20-Sep-18
US20180216067 2-Aug-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 29-Mar-18 2-Aug-18
US20180208897 26-Jul-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 19-Mar-18 26-Jul-18
US20180187154 5-Jul-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 20-Feb-18 5-Jul-18
US20180187153 5-Jul-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 20-Feb-18 5-Jul-18
US20180135012 17-May-18	MEMBRANE-RECEIVER COMPLEX THERAPEUTICS	Not Available	13-May-15 13-May-16 17-May-18
US20180030411 1-Feb-18	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 13-Oct-17 1-Feb-18
US20170369843 28-Dec-17	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 29-Mar-17 28-Dec-17
US20170174783 22-Jun-17	Single-Arm Monovalent Antibody Constructs and Uses Thereof	Not Available	10-May-12 20-Oct-16 22-Jun-17
US20160257932 8-Sep-16	GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER POLYPEPTIDE	Not Available	18-Nov-13 17-May-16 8-Sep-16
US20150335728 26-Nov-15	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09 18-Feb-14 26-Nov-15
US20150306212 29-Oct-15	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 12-Jun-15 29-Oct-15
US20150297677 22-Oct-15	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY	Children Medical Center Corporation	13-Dec-12 12-Dec-13 22-Oct-15
US20150182588 2-Jul-15	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13 23-Dec-14 2-Jul-15
US20150125449 7-May-15	Single-Arm Monovalent Antibody Constructs and Uses Thereof	Not Available	10-May-12 8-May-13 7-May-15
US20140113923 24-Apr-14	NOVEL ANTIVIRAL THERAPIES	Not Available	21-Sep-05 23-Apr-12 24-Apr-14
US20100247571 30-Sep-10	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	ACADEMIA SINICA	27-Mar-09 26-Mar-10 30-Sep-10
US20090042793 12-Feb-09	Novel Antiviral Therapies	BALZARINI JAN	21-Sep-05 21-Sep-06 12-Feb-09
US20080113409 15-May-08	Transient protein expression methods	HATEBOER GUUS	15-Apr-99 1-Jun-07 15-May-08

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434 · 979 · 7240



US10557119	Erythroid cells comprising phenylalanine ammonia lyase	RUBIUS THERAPEUTICS, INC.	18-Nov-13 10-May-19 11-Feb-20
US10344263	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 29-Mar-17 9-Jul-19
US10329531	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 13-Oct-17 25-Jun-19
US10307475	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09 18-Feb-14 4-Jun-19
US10301594	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 19-Nov-18 28-May-19
US10301593	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 19-Mar-18 28-May-19
US10253296	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13 28-Nov-17 9-Apr-19

1

SARS-CoV research specifically on ACE2 binding

Document number	Title	Assignee name	Priority date File date Issue date
US9415087	Compositions and methods for treating coronavirus infection	Ludwig-Maximilians-Universitaet Muenchen	11-Mar-14 8-May-15 16-Aug-16
US8541003	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	Protein Sciences Corporation	20-Jun-03 21-Jun-04 24-Sep-13
US7750123	Antibodies against SARS-CoV and methods of use thereof	Dana Farber Cancer Institute, Inc.	25-Nov-03 24-Nov-04 6-Jul-10
US7728110	Antibodies to SARS coronavirus	Amgen, Inc.	19-May-06 21-May-07 1-Jun-10
US7696330	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03 20-Jan-06 13-Apr-10
US7687475	RNA interference in respiratory epithelial cells	University of Iowa Research Foundation	9-Jul-04 16-Oct-07 30-Mar-10
US7629443	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	New York Blood Center, Inc.	2-Jun-04 8-Feb-06 8-Dec-09
US7604960	Transient protein expression methods	Crucell Holland B.V.	15-Apr-99 1-Jun-07 20-Oct-09

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434-979-7240



US7491489	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	The University of Hong Kong	22-Nov-04 28-Oct-05 17-Feb-09
US7320857	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	Chinese National Human Genome Center at Shanghai	9-Jul-04 9-Jul-04 22-Jan-08
US7297786	RNA interference in respiratory epithelial cells	University of Iowa Research Foundation	9-Jul-04 11-Jul-05 20-Nov-07
US7151163	Antiviral agents for the treatment, control and prevention of infections by coronaviruses	Sequoia Pharmaceuticals, Inc.	28-Apr-03 28-Apr-04 19-Dec-06
US20200079781 12-Mar-20	Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases	Not Available	5-Sep-18 1-Aug-19 12-Mar-20
US20200061185 27-Feb-20	PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE	The Scripps Research Institute	25-Oct-16 25-Oct-17 27-Feb-20
US20200009244 9-Jan-20	NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS	Not Available	13-Jun-18 13-Jun-19 9-Jan-20
US20190328865 31-Oct-19	IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION	Not Available	28-Jul-14 17-Nov-17 31-Oct-19
US20190256579 22-Aug-19	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The U.S.A., as represented by the Secretary, Department of Health and Human Services	24-Feb-15 3-May-19 22-Aug-19
US20190194299 27-Jun-19	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25-Apr-14 19-Nov-18 27-Jun-19
US20190192691 27-Jun-19	REGULATED BIOCIRCUIT SYSTEMS	Not Available	11-Apr-16 11-Apr-17 27-Jun-19
US20180334480 22-Nov-18	CORONAVIRUSES EPIPOPE-BASED VACCINES	RAMOT AT TEL-AVIV UNIVERSITY LTD.	17-Sep-15 15-Sep-16 22-Nov-18
US20180332885 22-Nov-18	REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME	Not Available	11-May-05 25-May-18 22-Nov-18
US20180244756 30-Aug-18	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The United States of America, as Represented by the Secretary, Dept. of Health and Human Services	24-Feb-15 24-Feb-16 30-Aug-18
US20180230447 16-Aug-18	ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)	Northwestern University	24-Jan-17 24-Jan-18 16-Aug-18
US20180177860 28-Jun-18	VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD THEREFOR	Not Available	11-Jun-15 7-Jun-16 28-Jun-18
US20170158752 8-Jun-17	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25-Apr-14 27-Apr-15 8-Jun-17
US20170055566 2-Mar-17	REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME	Not Available	11-May-05 22-Aug-16 2-Mar-17
US20160376321 29-Dec-16	A NOVEL SARS IMMUNOGENIC COMPOSITION	BAYLOR COLLEGE OF MEDICINE	26-Nov-13 21-Nov-14 29-Dec-16

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434 · 979 · 7240



US20160082074 24-Mar-16	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN	11-Mar-14 8-May-15 24-Mar-16
US20150297677 22-Oct-15	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY	Children Medical Center Corporation	13-Dec-12 12-Dec-13 22-Oct-15
US20150275183 1-Oct-15	Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor	Not Available	23-Sep-12 23-Sep-13 1-Oct-15
US20150150878 4-Jun-15	Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins	Not Available	4-Apr-12 4-Apr-13 4-Jun-15
US20140174460 26-Jun-14	REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME	VECTOR TOBACCO INC.	11-May-05 10-Dec-13 26-Jun-14
US20130216566 22-Aug-13	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	ADAMS DANIEL	20-Jun-03 21-Jun-04 22-Aug-13
US20130196903 1-Aug-13	Multimeric Inhibitors of Viral Fusion and Uses Thereof	JV BIO SRL	11-Aug-10 11-Aug-11 1-Aug-13
US20100204286 12-Aug-10	METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS	BYRNES JOHN J	12-Feb-09 11-Feb-10 12-Aug-10
US20100172917 8-Jul-10	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03 16-Nov-09 8-Jul-10
US20100150923 17-Jun-10	FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES	Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences	20-Jun-05 13-Jun-06 17-Jun-10
US20100092470 15-Apr-10	ANTIBODIES, ANALOGS AND USES THEREOF	ICB International, Inc.	22-Sep-08 21-Sep-09 15-Apr-10
US20100047767 25-Feb-10	PATHOGEN BINDING	ITI SCOTLAND LIMITED	5-Feb-07 4-Feb-08 25-Feb-10
US20100035848 11-Feb-10	THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT	BARNES THOMAS MICHAEL	10-Mar-08 10-Mar-09 11-Feb-10
US20090304683 10-Dec-09	Soluble Fragments of The Sars-Cov Spike Glycoprotein	DIMITROV DIMITER S	19-Jan-07 19-Jan-07 10-Dec-09
US20090186014 23-Jul-09	METHOD FOR TREATMENT OF PANCREATITIS	Ore Pharmaceuticals Inc.	10-Oct-07 9-Oct-08 23-Jul-09
US20090130691 21-May-09	SCREENING PROTEINASE MODULATORS USING A CHIMERIC PROTEIN AND SKI-I PROPROTEIN CONVERTASE SUBSTRATES AND INHIBITORS	Institut de Recherches Cliniques de Montreal	16-Sep-05 14-Sep-06 21-May-09
US20090099259 16-Apr-09	Method for regulating gene expression	ANTHONY JOSHUA	28-Feb-06 28-Feb-07 16-Apr-09
US20090098530 16-Apr-09	Cell Line For Producing Coronaviruses	CRUCCELL HOLLAND B.V.	22-Jul-05 21-Jul-06 16-Apr-09
US20090083865 26-Mar-09	Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof	CHAN TEH-SHENG	11-Jan-06 11-Jan-07 26-Mar-09

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434-979-7240



US20080248043 9-Oct-08	Antibodies to SARS coronavirus	Amgen Inc.	19-May-06 21-May-07 9-Oct-08
US20080234345 25-Sep-08	METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT	Gene Logic Inc.	8-Sep-06 7-Sep-07 25-Sep-08
US20080159962 3-Jul-08	Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries	IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE GMBH	19-May-05 19-May-06 3-Jul-08
US20080113409 15-May-08	Transient protein expression methods	HATEBOER GUUS	15-Apr-99 1-Jun-07 15-May-08
US20080107650 8-May-08	METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT	Gene Logic Inc.	8-Sep-06 7-Sep-07 8-May-08
US20080044437 21-Feb-08	Encapsidation System for Production of Recombinant Virus-Like Particles	CHEN QUN	2-Sep-04 1-Sep-05 21-Feb-08
US20070298498 27-Dec-07	Adenoviral Amplicon and Producer Cells for the Production of Replication-Defective Adenoviral Vectors, Methods of Preparation and Use Thereof	CATALUCCI DANIELE	2-Nov-04 27-Oct-05 27-Dec-07
US20070238681 11-Oct-07	MODULATION OF ACE2 EXPRESSION	BENNETT C F	7-Nov-06 7-Dec-06 11-Oct-07
US20070203073 30-Aug-07	SARS and Ebola inhibitors and use thereof, and methods for their discovery	BATES PAUL	22-Jun-05 21-Jun-06 30-Aug-07
US20070185044 9-Aug-07	Modulation of ace2 expression	BENNETT C F	8-Mar-05 8-Mar-05 9-Aug-07
US20070185027 9-Aug-07	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES	SEQUOIA PHARMACEUTICALS, INC.	28-Apr-03 9-Nov-06 9-Aug-07
US20070003577 4-Jan-07	Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections	SUBBARAO KANTA	28-Jun-05 27-Jun-06 4-Jan-07
US20060258577 16-Nov-06	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES	ERICKSON JOHN W	28-Apr-03 28-Apr-04 16-Nov-06
US20060257852 16-Nov-06	Severe acute respiratory syndrome coronavirus	Chiron Corporation	10-Apr-03 9-Apr-04 16-Nov-06
US20060240551 26-Oct-06	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	HE YUXIAN	2-Jun-04 8-Feb-06 26-Oct-06
US20060240515 26-Oct-06	Soluble fragments of the SARS-CoV spike glycoprotein	DIMITROV DIMITER S	21-Jul-03 19-Jan-06 26-Oct-06
US20060199176 7-Sep-06	Coronavirus S peptides	CHONG PELE C S	15-Jul-04 14-Jul-05 7-Sep-06
US20060121580 8-Jun-06	Binding molecules against SARS-coronavirus and uses thereof	CRUCCELL	22-Jul-03 20-Jan-06 8-Jun-06
US20060110758 25-May-06	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	UNIV HONG KONG	22-Nov-04 28-Oct-05 25-May-06

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902

T: 434 · 979 · 7240



US20060093616 4-May-06	Process for vaccinating eucaryotic hosts and for protecting against SARS-CoV infection	ALTMAYER RALF	29-Sep-04 28-Sep-05 4-May-06
US20050249739 10-Nov-05	Antibodies against SARS-CoV and methods of use thereof	MARASCO WAYNE	25-Nov-03 24-Nov-04 10-Nov-05
US20050203038 15-Sep-05	Modulation of ACE2 expression		10-Mar-04 10-Mar-04 15-Sep-05
US20050113298 26-May-05	Receptor binding peptides derived from the SARS S protein		15-Sep-03 13-Sep-04 26-May-05
US20050112554 26-May-05	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	HENG XU RUI	9-Jul-04 9-Jul-04 26-May-05
US10443049	Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)	Northwestern University	24-Jan-17 24-Jan-18 15-Oct-19
US10301377	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use	The United States of America, as Represented by the Secretary, Department of Health and Human Services	24-Feb-15 24-Feb-16 28-May-19
US10131704	Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof	DANA-FARBER CANCER INSTITUTE, INC.	25-Apr-14 27-Apr-15 20-Nov-18

ANIMATE VALUE™

Info@m-cam.com

513 E Main Street #2014 Charlottesville, VA 22902


T: 434 · 979 · 7240

SCHEDULE 2

Tables of Coronavirus Patent Filings and Published Scientific Articles on Coronavirus

TABLE I


All patent filings since 1998 (over 5,000) referencing SARS Coronavirus.



	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	total
file	0	0	0	0	0	120	186	280	324	292	254	176	148	107	148	171	207	266	251	156	124	296	5111	
issue	0	0	0	0	1	69	135	178	224	278	334	391	531	631	814	831	820	804	813	848	878	931	5111	
priority	10	12	29	38	129	506	487	408	335	370	279	256	303	279	322	330	348	342	208	95	25	0	0	5111
total	10	12	29	38	129	627	888	833	842	891	810	778	892	847	974	1015	1186	1228	1163	1024	800	777	240	15333

TABLE 2

All scientific research papers that included the word “coronavirus” in the title or abstract.



MEGAN THIELKING/STAT
SOURCE: ANALYSIS OF CONTENT IN WEB OF SCIENCE CORE COLLECTION, CONDUCTED FEB. 6, 2020

STAT

“The number of scientific papers that included the word “coronavirus” in the title or abstract jumped dramatically after the SARS outbreak began in 2002, according to an analysis of scientific content in the Web of Science Core Collection conducted for STAT. The database culls papers from more than 21,000 peer-reviewed, scholarly journals around the globe.

“But when concerns faded as the outbreak was contained, and multiyear grants dried up, the pace of publication slowed. There were just 594 papers published on coronaviruses in 2011, compared to a peak of 1,007 papers in 2004.”

STAT, *Fluctuating funding and flagging interest hurt coronavirus research, leaving crucial knowledge gaps*, Helen Branswell, Megan Thielking, February 10, 2020; <https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/>